Biopharma R&D laboratory design
Key Statistics
Client
EMD Serono
Year
Current
PM Group Office
US East Coast
Cost
$57m USD
Size
145,000 sqft

EMD Serono’s new biopharmaceutical Research and Development laboratory facility at its growing R&D hub in Billerica, MA, will focus on advancing research in oncology, immuno-oncology and immunology.

Do you have a pharmaceutical project? Talk to our experts.

Andy Rayner
Andy Rayner

Pharmaceutical Sector Director

A mixed use development

PM Group’s architects designed this new 145,000 sq ft mixed use office and R&D laboratories development. It incorporates a central campus cafeteria and is connected to existing adjacent facilities via bridges.

Flexible state-of-the-art R&D laboratories

The R&D area includes approx. 30,000 sq.ft of flexible lab space adaptable for future needs. Benches can be arranged to suit the research and the user. Regularly spaced overhead service panels provide utilities to the bench top. As benches are rearranged, utilities have ‘Plug and Play’ capability to suit the science.

 

With a focus on sustainability, the building was designed and constructed for LEED Gold and WELL Platinum certification.

About the WELL Standard

WELL 2.0 is the WELL Building Institute’s evidence-based system for measuring, certifying and monitoring building performance features that address well-being of users.

The WELL Building Standard/ WELL V2 is the leading performance standard for health and wellness in the built environment, It incorporates 10 concepts including Air, Water, Nourishment, Light, Movement, Thermal Comfort, Sound, Materials, Mind and Community.

WELL focuses exclusively on the health and wellness of building occupants taking a holistic approach in the built environment addressing behavior, operations and design, and is intended to promote health, happiness and productivity of employees.

About EMD Serono

EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada. The company is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and multiple sclerosis. EMD Serono continues to strengthen its innovation footprint in both the U.S. and Darmstadt, Germany where it’s global R&D headquarters are located, with the goal of delivering transformational value to patients around the world.

 

Andy Rayner

Pharmaceutical Sector Director